Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics insider Richard Heyman filed a notice of proposed sale under Rule 144 covering up to 1,230 shares of common stock. The planned sale through Jefferies LLC on the Nasdaq has an aggregate market value of $32,865.60, with 59,000,000 shares outstanding. The approximate sale date indicated is February 17, 2026. In the past three months, Heyman has sold Enliven securities in three transactions totaling 8,015 shares for $200,655.12, 4,285 shares for $107,125.60, and 1,230 shares for $32,901.55.
Enliven Therapeutics filed a notice of proposed insider sales under Rule 144. The filing covers up to 45,000 shares of common stock, with an aggregate market value of $1,202,400.00, to be sold through Jefferies LLC on or about February 17, 2026 on the NASDAQ exchange.
The 45,000 shares were acquired on August 9, 2022 via stock options from Enliven Therapeutics Inc. The filing also notes that 59,000,000 shares of common stock were outstanding. The seller represents they are not aware of undisclosed material adverse information about the company.
Vestal Point Capital has reported a significant passive ownership stake in Enliven Therapeutics, Inc. Through a fund and a managed account, Vestal Point and its CIO Ryan Wilder beneficially own 3,830,000 shares of Enliven common stock, representing 6.5% of the company’s outstanding shares.
The filing shows Vestal Point and Wilder share voting and dispositive power over these shares, while the Vestal Point fund and account are entitled to dividends and sale proceeds. The ownership percentage is based on 59,347,317 Enliven shares outstanding as of October 31, 2025. The stake is certified as being held in the ordinary course of business without the purpose of influencing control.
Enliven Therapeutics’ chief scientific officer, Joseph P. Lyssikatos, reported an indirect sale of company stock through a family trust. On February 6, 2026, The Lyssikatos Revocable Trust sold 5,000 shares of Enliven common stock at a weighted average price of $29.0438 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.
After this transaction, the trust, for which Lyssikatos serves as trustee, beneficially owned 740,188 shares of Enliven Therapeutics common stock, reported as indirectly owned.
ELVN insider Andrew Phillips filed a notice to sell 21,844 shares of common stock through Morgan Stanley Smith Barney on or about February 2, 2026, on NASDAQ, with an aggregate market value of $611,719.38.
The shares were acquired the same day via a stock option exercise paid in cash. Phillips also sold 1,520 common shares for $42,564.10 on January 22, 2026. Common shares outstanding were 59,347,317 at the time referenced.
The Lyssikatos Revocable Trust 12/15/2011, for which Enliven Therapeutics’ Chief Scientific Officer Joseph P. Lyssikatos serves as trustee, reported pre‑planned sales of company common stock. On January 20, 2026, the trust sold 5,491 shares at a weighted average price of $26.373 per share and a further 14,509 shares at a weighted average price of $26.8995 per share, each under a Rule 10b5-1 trading plan adopted on November 15, 2024. Following these transactions, the trust held 745,188 shares of Enliven Therapeutics common stock indirectly attributable to the reporting person.
Enliven Therapeutics, Inc. director Richard A. Heyman reported planned sales of company common stock by related entities. On January 20, 2026, the Heyman Daigle Trust, for which he serves as trustee, sold 512 shares at $26.4592 and 718 shares at $26.956 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024. After these transactions, the trust held 23,877 shares beneficially for him. Heyman also reported 123,673 shares held directly and 25,545 shares held indirectly through RAHD Capital LLC, where he is a managing member.
Enliven Therapeutics investor plans to sell 1,230 common shares. The planned sale is to be executed through Jefferies LLC on Nasdaq, with an approximate sale date of 01/20/2026 and an aggregate market value of $32,853.30 for this block. The filing notes that 59,000,000 shares of the issuer’s stock were outstanding.
The seller acquired these 1,230 shares as founder shares from Enliven Therapeutics on 01/25/2020. Over the past three months, Richard Heyman has sold additional Enliven securities in two transactions: 8,015 shares on 01/08/2026 for gross proceeds of $200,655.12 and 4,285 shares on 01/09/2026 for gross proceeds of $107,125.60. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Enliven’s current or prospective operations.
Enliven Therapeutics, Inc. reported an insider transaction involving its Chief Operating Officer, Anish Patel, through an associated family trust. On January 9, 2026, The Patel / Dong Family Trust, for which Patel serves as trustee, sold 48,057 shares of Enliven common stock at a weighted average price of $27.9842, and an additional 243 shares at $28.50.
The filing states these sales were made under a Rule 10b5-1 trading plan adopted on September 30, 2024, which is a pre-arranged plan for trading the issuer’s equity securities. After these transactions, the trust held 215,011 shares of Enliven common stock, all reported as indirectly owned.
Enliven Therapeutics, Inc. insider activity shows that a trust associated with Chief Scientific Officer Joseph P. Lyssikatos sold a total of 132,500 shares of common stock in early January 2026. The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee, reported sales of 7,500 shares at a weighted average price of $20.1282 on 01/08/2026, followed by 33,802 shares at $24.9238 on the same date. On 01/09/2026, the trust sold 41,198 shares at a weighted average price of $24.9008 and 50,000 shares at $29.1343. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024, and after the final sale, the trust beneficially owned 765,188 shares.